Enhanced survival in resectable duodenal adenocarcinoma with adjuvant chemotherapy: evidence from a retrospective study.

Front Oncol · 2026 · PMC13160806 · PMID 42130629

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp=0.08so close (0.05 < p ≤ 0.1)

9.6 months, p=0.02), while stage IIB showed a trend towards improved OS (63.6 vs. 25.9 months, p=0.08).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Although we observed an extension in OS among stage IIIB DA patients receiving adjuvant chemotherapy, this difference did not reach statistical significance, possibly due to our limited sample size and a substantial number of patients not reaching the study endpoint.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.